Jaguar Health (NASDAQ:JAGX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Jaguar Health (NASDAQ:JAGX) in a report issued on Tuesday morning. The firm issued a sell rating on the biotechnology company’s stock.

Jaguar Health Stock Up 3.2 %

Shares of NASDAQ JAGX opened at $0.21 on Tuesday. The company has a debt-to-equity ratio of 6.33, a quick ratio of 1.34 and a current ratio of 2.00. Jaguar Health has a 52-week low of $0.05 and a 52-week high of $1.22. The firm has a 50 day moving average price of $0.10 and a two-hundred day moving average price of $0.18.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.